Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Share:
Related BMY
The Most Notable Abstracts Released Ahead Of ASCO 2017
Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP (GuruFocus)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

View Comments and Join the Discussion!